ArticlePloS one2026
Evaluation of Colombian silk fibroin hydrogels functionalized with recombinant LSECtin for intervertebral disc tissue engineering.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study evaluated the potential of Colombian silk fibroin hydrogels functionalized with recombinant LSECtin (rLSECtin) for intervertebral disc tissue engineering. In silico analysis indicated that rLSECtin may interact with glycans similar to those found in human adipose-derived stem cells (ADSCs) through residues Asn105, Asp106, Glu93, Asn87, and Glu85, which coordinate calcium to form hydrogen bonds with GlcNAc hydroxyl groups. rLSECtin was successfully produced, purified, and incorporated into silk fibroin hydrogels. Thermal analysis showed that the hydrogels were resistant to sterilization, and rheological studies demonstrated predominantly elastic, gel-like behavior. The secondary structure of the hydrogels was largely determined by α-helical content, which is related to silk I with β-sheets also contributing as a result of sonication-induced structuring. Metabolic activity assays indicated that rLSECtin was associated with increased ADSC metabolic activity under two-dimensional conditions, whereas hydrogels containing rLSECtin maintained cell viability, as confirmed by cell viability assays. Differentiated constructs exhibited glycosaminoglycan-rich extracellular matrix and chondrocyte-like morphology, whereas rLSECtin-functionalized hydrogels showed increased transcription of SOX9, ACAN, and COL2A1, along with elevated COL10A1 of uncertain significance for nucleus pulposus stability. Overall, Colombian silk fibroin hydrogels provide a mechanically stable and cytocompatible platform relevant for nucleus pulposus tissue engineering, in which rLSECtin appears to act primarily as a biochemical modulator rather than a structural modifier. These findings support a proof of concept for lectin-functionalized biomaterials in intervertebral disc regeneration. However, further studies, including mechanistic validation of glycan-lectin interactions, protein-level confirmation, quantitative extracellular matrix analysis, and evaluation of signaling pathways, are required to establish functional and translational relevance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.